Qube Research & Technologies Ltd

Position in FATE — Fate Therapeutics Inc

CIK 1729829 LONDON, X0

Position in FATE

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,561,005

+$1,524,528 QoQ

Shares Held

578,150

+5447.4% QoQ

Ownership

0.483%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#21

of 156 holders

Holding Since

Mar 2021

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Qube Research & Technologies Ltd holds $2,437,858,262 across 168 Biotechnology names. FATE ranks #107 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	798,715	$240,437,176
2	INSM	INSMED Inc	1,682,334	$179,370,451
3	REGN	Regeneron Pharmaceuticals, Inc.	221,607	$138,180,828
4	ROIV	Roivant Sciences Ltd.	3,454,496	$122,254,613
5	AXSM	Axsome Therapeutics, Inc.	426,336	$104,354,262
6	APGE	Apogee Therapeutics, Inc.	659,678	$87,559,060
7	TVTX	Travere Therapeutics, Inc.	1,443,230	$81,989,896
8	RPRX	Royalty Pharma plc	1,412,112	$79,177,119

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,561,005	578,150	+5447.4%	Shares	Sole	2026-08-14
2024-09-30	$36,477	10,422	-70.3%	Shares	Sole	2024-11-14
2024-06-30	$115,239	35,134	+210.6%	Shares	Sole	2024-08-14
2024-03-31	$83,015	11,310	-78.4%	Shares	Sole	2024-05-14
2023-12-31	$196,133	52,442	-86.5%	Shares	Sole	2024-02-13
2023-09-30	$823,102	388,256	+117.3%	Shares	Sole	2023-11-13
2023-06-30	$850,359	178,647	+965.0%	Shares	Sole	2023-08-14
2023-03-31	$95,611	16,774	-96.6%	Shares	Sole	2023-05-15
2022-12-31	$4,964,098	491,982	+2030.7%	Shares	Sole	2023-02-14
2022-09-30	$517,446	23,090	+78.2%	Shares	Sole	2022-11-14
2021-09-30	$768,020	12,958	-42.5%	Shares	Sole	2021-11-12
2021-06-30	$1,955,899	22,536	+140.9%	Shares	Sole	2021-08-13
2021-03-31	$771,237	9,354	—	Shares	Sole	2021-05-14
No filing history on record for this holder in this stock.